Effective practical management of patients with atrial fibrillation when using new oral anticoagulants

References

• Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009; 104:1534–9.
   PubMed Web of Science ®Google Scholar
• Stefansdottir H, Aspelund T, Gudnason V, Arnar DO. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011;13:1110–17.
   PubMed Web of Science ®Google Scholar
• Barrios V, Calderon A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol. 2012;65:47–53.
   PubMed Web of Science ®Google Scholar
• Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147:1561–4.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Coumadin (warfarin sodium) Prescribing Information. 2011. Available at: http://packageinserts.bms.com/pi/pi_coumadin.pdf (accessed 6 October 2014).
   Google Scholar
• Bristol-Myers Squibb, Pfizer EEIG. Eliquis® (apixaban) Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf (accessed 15 July 2014).
   Google Scholar
• Boehringer Ingelheim International GmbH. Pradaxa® (dabigatran etexilate) Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (accessed 2 May 2014).
   Google Scholar
• Bayer Pharma AG. Xarelto® (rivaroxaban) Summary of Product Characteristics. 2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf (accessed 1 July 2014).
   Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864–70.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Nieuwlaat R, Pisters R, Lane D, Crijns H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–72.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC Jr, Cigarroa JE, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:e1–76.
   PubMed Web of Science ®Google Scholar
• Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28:125–36.
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141: e531S–75S.
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33: 2719–47.
   PubMed Web of Science ®Google Scholar
• Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing. 2011;40: 675–83.
   PubMed Web of Science ®Google Scholar
• Devereaux PJ, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J. 2001;323:1218–22.
   PubMed Web of Science ®Google Scholar
• Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164:880–4.
   PubMed Web of Science ®Google Scholar
• Gomes T, Mamdani MM, Holbrook AM, Paterson JM, Juurlink DN. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med. 2012;172:1687–9.
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864–72.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.
   PubMed Web of Science ®Google Scholar
• Halperin JL, Bloomgarden Z, Hellkamp A, Lokhnygina Y, Patel M, Becker R, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a subgroup analysis of the ROCKET AF trial. American Heart Association Scientific Sessions 2012. Los Angeles, United States, 3–7 November 2012; Abstract A15544.
   Google Scholar
• Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125:669–76.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Hohloser SH, Oldgren J, Andersson U, Connolly S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation - a RE-LY trial analysis. American Heart Association Scientific Sessions 2013. Dallas, USA, 16–20 November 2013; Abstract 13190.
   Google Scholar
• Gelbricht V, Koehler C, Werth S, Haensel U, Schreier T, Eulitz M, et al. Real life efficacy and safety of rivaroxaban for acute VTE treatment – first results of the Prospective Noac Registry (NCT01588119). Blood (ASH Annual Meeting Abstracts). 2012;120. Abstract 1159.
   Web of Science ®Google Scholar
• Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL, et al. Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care. 2012;18:139–46.
   PubMed Web of Science ®Google Scholar
• Francis KM, Siu K, Yu C, Alvrtsyan H, Rao Y, Walker DR, et al. Persistence among patients with non-valvular atrial fibrillation beginning dabigatran or warfarin. Blood (ASH Annual Meeting Abstracts). 2012;120. Abstract 365.
   Google Scholar
• Werth S, Koehler C, Gelbricht V, Haensel U, Tittl L, Beyer-Westendorf I, et al. Real life efficacy and safety of dabigatran for stroke prevention in atrial fibrillation – first results of the prospective NOAC registry (NCT01588119). Blood (ASH Annual Meeting Abstracts). 2012;120. Abstract 502.
   Web of Science ®Google Scholar
• Kreutz R. A clinical and pharmacological assessment of once-daily versus twice-daily dosing for rivaroxaban. J Thromb Thrombolysis. 2014;38:137–49.
   PubMed Web of Science ®Google Scholar
• Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625–51.
   PubMed Web of Science ®Google Scholar
• NPS RADAR. Rivaroxaban (Xarelto) for stroke prevention in non- valvular atrial fibrillation. 2012. Available at: http://www.nps.org.au/__data/assets/pdf_file/0020/218144/Rivaroxaban-NVAF.pdf (accessed 17 July 2014).
   Google Scholar
• Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med. 1999;159:677–85.
   PubMed Web of Science ®Google Scholar
• Jacobs JM, Stessman J. New anticoagulant drugs among elderly patients is caution necessary?: Comment on “The use of dabigatran in elderly patients”. Arch Intern Med. 2011;171:1287–8.
   PubMed Web of Science ®Google Scholar
• Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation. 2012;126:343–8.
   PubMed Web of Science ®Google Scholar
• Witt DM, Delate T, Garcia DA, Clark NP, Hylek E, Ageno W, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med. 2012;172:1484–91.
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011;117:6091–9.
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep. 2014;16:480.
   PubMed Web of Science ®Google Scholar
• Hagii J, Tomita H, Metoki N, Saito S, Shiroto H, Hitomi H, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. Stroke. 2014;45:2805–7.
   PubMed Web of Science ®Google Scholar
• Crowther M, Kitt M, Lorenz T, Mathur V, Lu G, Hutchaleelaha A, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect Factor Xa inhibitors. XXIV Congress of the International Society on Thrombosis and Haemostasis. Amsterdam, Netherlands, 29 June–4 July 2013; Abstract AS 20.1.
   Google Scholar
• Crowther M, Mathur A, Kitt M, Genmin L, Conley PB, Hollenbach S, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood (ASH Annual Meeting Abstracts). 2013;122. Abstract 3636.
   Web of Science ®Google Scholar
• Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62.
   PubMed Web of Science ®Google Scholar
• Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost. 2014;111:808–16.
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655–711.
   PubMed Web of Science ®Google Scholar
• Kawiorski MM, Alonso-Canovas A, de Felipe Mimbrera A, Sainz de la Maza S, Alvarez-Velasco R, Zarza B, et al. Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment. Thromb Haemost. 2014;111:557–8.
   PubMed Web of Science ®Google Scholar
• Pfeilschifter W, Bohmann F, Baumgarten P, Mittelbronn M, Pfeilschifter J, Lindhoff-Last E, et al. Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke. Ann Neurol. 2012;71:624–33.
   PubMed Web of Science ®Google Scholar
• Bohmann F, Mirceska A, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C, et al. No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke. PLoS One. 2012;7:e40804.
   PubMed Web of Science ®Google Scholar
• Sun L, Zhou W, Ploen R, Zorn M, Veltkamp R. Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia. Thromb Haemost. 2013;110:153–61.
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J. 2005;26:2422–34.
   PubMed Web of Science ®Google Scholar
• Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423–34.
   PubMed Web of Science ®Google Scholar
• Hersi A, Alhabib KF, Alsheikh-Ali AA, Sulaiman K, Alfaleh HF, Alsaif S, et al. Prognostic significance of prevalent and incident atrial fibrillation among patients hospitalized with acute coronary syndrome: Findings from the Gulf RACE-2 Registry. Angiology. 2012;63:466–71.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30:1038–45.
   PubMed Web of Science ®Google Scholar
• Sørensen R, Gislason G. Triple antithrombotic therapy: risky but sometimes necessary. Rev Esp Cardiol (Engl Ed). 2014;67:171–5.
   PubMed Web of Science ®Google Scholar
• Janssen Scientific Affairs L. A study exploring two strategies of rivaroxaban (JNJ39039039; BAY-59-7939) and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). 2014. Available at: http://clinicaltrials.gov/ct2/show/NCT01830543 (accessed 28 July 2014).
   Google Scholar
• O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–140.
   PubMed Web of Science ®Google Scholar
• Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33:2569–619.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010; 103:13–28.
   PubMed Web of Science ®Google Scholar
• Stanley AG, Fletcher S, Tan A, Barnett DB. Is warfarin a contraindication to thrombolysis in acute ST elevation myocardial infarction? Heart. 2006;92:1145–6.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31:1311–18.
   PubMed Web of Science ®Google Scholar
• Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;121:2067–70.
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, de Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–15.
   PubMed Web of Science ®Google Scholar
• Obonska K, Navarese EP, Lansky A, Tarantini G, Rossini R, Kozinski M, et al. Low-dose of oral Factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Atherosclerosis. 2013;229:482–8.
   PubMed Web of Science ®Google Scholar
• Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374:29–38.
   PubMed Web of Science ®Google Scholar
• Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study exploring two strategies of rivaroxaban and one of oral vitamin K antagonist in patients with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01830543 (accessed 26 September 2014).
   Google Scholar
• Mak KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2:e001592.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Rosenzweig M, Lane DA, et al. Myocardial ischemic events in ‘real world’ patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med. 2014;127:329–36.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Drug Safety Communication: FDA study of Medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. 2014. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm (accessed 16 July 2014).
   Google Scholar
• Lip GYH, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155–79.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Gross PL. New oral anticoagulants: which one should my patient use? Hematology Am Soc Hematol Educ Program. 2012;2012: 536–40.
   PubMed Web of Science ®Google Scholar